Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.
- Technegas approved for clinical use at US NIH
- Installation expected soon following purchase order
- Leverages five-year Federal Supply Schedule agreement
- Supports expanded use beyond pulmonary embolism
- Strengthens Cyclopharm’s US institutional credibility
A Strategic Win at the NIH
Cyclopharm Limited, an ASX-listed radiopharmaceutical company, has announced that its flagship product Technegas has been approved for clinical use at the National Institutes of Health (NIH) in Bethesda, Maryland. This approval is more than a routine contract; it represents a significant strategic milestone in Cyclopharm’s ongoing US expansion efforts.
The NIH Clinical Centre is renowned globally as the largest hospital dedicated exclusively to clinical research. Securing a purchase order and moving towards installation at such a prestigious institution not only validates Technegas’s clinical utility but also enhances Cyclopharm’s standing within the US healthcare ecosystem.
Leveraging Federal Procurement Channels
This development builds on Cyclopharm’s five-year Federal Supply Schedule (FSS) agreement secured in March 2025, which streamlines procurement across US federal healthcare institutions, including Veterans Affairs hospitals and military treatment facilities. The NIH order underscores the strategic value of this federal contracting platform, facilitating broader adoption of Technegas across influential government medical centres.
Technegas will initially be used for clinical ventilation imaging within NIH’s protocol-driven programs, primarily targeting pulmonary embolism diagnosis. However, the potential applications extend well beyond this, encompassing chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, oncology-related pulmonary complications, and longitudinal lung function studies.
Expanding Clinical Horizons Beyond Pulmonary Embolism
The unique properties of Technegas; delivering true functional ventilation imaging with high peripheral lung deposition and significantly lower radiation doses compared to traditional imaging methods; position it as a valuable tool for a range of pulmonary conditions. NIH’s leadership in translational research offers a high-visibility platform to explore and validate these broader clinical applications, potentially influencing future clinical guidelines and practice patterns.
James McBrayer, Cyclopharm’s Managing Director and CEO, highlighted the importance of this milestone, noting that the NIH installation not only supports pulmonary embolism imaging but also strengthens the company’s institutional credibility and long-term growth prospects in the US market.
Commercial and Market Implications
From a commercial perspective, the NIH approval is expected to drive increased system utilisation and recurring consumables revenue, as expanded clinical use translates into more frequent procedures. Moreover, NIH-led research often catalyses multicentre collaborations and wider adoption, potentially opening doors to further contracts and installations across federal and private healthcare providers.
While the announcement does not disclose specific financial terms or detailed timelines beyond the imminent installation, the strategic significance is clear – Cyclopharm is positioning Technegas as a key player in US pulmonary imaging, supported by robust federal procurement channels and high-profile institutional endorsements.
Bottom Line?
Cyclopharm’s NIH breakthrough sets the stage for broader US adoption and deeper clinical validation of Technegas.
Questions in the middle?
- How quickly will NIH-led research translate into wider clinical adoption of Technegas?
- What financial impact will the NIH installation and subsequent federal contracts have on Cyclopharm’s revenue?
- Could Technegas gain approval for additional pulmonary indications beyond pulmonary embolism in the near term?